The physical niche provided by HepG2 cells in the co-culture model protected HUVEC-C3 cells from the inhibitors treatments, which illustrated the true clinical situation in HCC patients, where anti-VEGF therapies often have transient effects with relapse and tumor progression6. This evidence concerns the gene VEGFA and neoplasm.